Role of Transposable Elements in Septic Immune Aging

a study on Sepsis Sepsis and Septic Shock Sepsis With Multiple Organ Dysfunction (MOD) Sepsis With Acute Organ Dysfunction Sepsis, Severe Sepsis at Intensive Care Unit Sepsis, Severe Sepsis and Septic Shock Sepsis, Septic Shock

Summary

Eligibility
for people ages 18 years and up (full criteria)
Healthy Volunteers
healthy people welcome
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Alexendar R Perez, M.D., Ph.DJudith Hellman, M.D.Matthieu Legrand, M.D., Ph.D
Headshot of Matthieu Legrand
Matthieu Legrand

Description

Summary

The goal of this observational study is to learn about how transposable element levels affect the patient outcomes in sepsis. The main questions it aims to answer is:

  1. Do transposable elements prematurely age the immune systems of patients with sepsis?
  2. Do transposable elements correlate with increased mortality in patients with sepsis in the ICU?
  3. Do transposable elements correlate with increased amount of secondary infections in patients with sepsis in the ICU?

Participants will have blood drawn from them but will not be subjected to additional interventions.

Keywords

Sepsis, Sepsis and Septic Shock, Sepsis With Multiple Organ Dysfunction (MOD), Sepsis With Acute Organ Dysfunction, Sepsis, Severe, Sepsis at Intensive Care Unit, Sepsis, Severe Sepsis and Septic Shock, Sepsis, Septic Shock, Transposable Elements, Immune Aging, Mortality, Secondary Infections, Critical Care Medicine (ICU), Toxemia, Septic Shock, Shock, RNA and DNA Sequencing

Eligibility

You can join if…

Open to people ages 18 years and up

  • Age 18 or older
  • Admitted to ICU with sepsis (Sepsis 3 Criteria)
  • SOFA score of at least 2 at time of enrollment

You CAN'T join if...

  • Patients on organ transplantation immunosuppression
  • Patients with preexisting leukopenia
  • Cancer patients receiving CAR-T therapy
  • Patients who are under 18 years of age or otherwise deemed pediatric
  • Patients with an ongoing bleeding diathesis (ie: DIC, hemorrhagic shock)
  • Patients with a chronic hemoglobin below 7.0
  • Patients who, prior to their ICU admission, are blood transfusion dependent

Location

  • UCSF accepting new patients
    San Francisco California 94143 United States

Lead Scientists at UCSF

  • Alexendar R Perez, M.D., Ph.D
  • Judith Hellman, M.D.
    My research program is focused on basic and translational research on sepsis and other forms of inflammation-driven acute organ failure ("Inflammatory Critical Illness"). Sepsis and multiple organ failure are leading causes of death in the Intensive Care Unit.
  • Matthieu Legrand, M.D., Ph.D
    Dr. Legrand is a clinician scientist practicing critical care medicine and anesthesiology. His professional interests include the use of cardiovascular medications in critical illness and major surgery, treatments and pathophysiology of sepsis, and acute kidney injury.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT06809868
Study Type
Observational [Patient Registry]
Participants
Expecting 116 study participants
Last Updated
Contact us about this trial